Compare · ARGX vs MGX
ARGX vs MGX
Side-by-side comparison of argenx SE (ARGX) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $56.09B, about 1252.0x MGX ($44.8M).
- Over the past year, ARGX is up 66.9% and MGX is down 15.8% - ARGX leads by 82.7 points.
- MGX has been more active in the news (7 items in the past 4 weeks vs 4 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- argenx SE
- Metagenomi Therapeutics Inc.
- Price
- $904.59+3.04%
- $1.20-0.83%
- Market cap
- $56.09B
- $44.8M
- 1M return
- +12.45%
- -7.69%
- 1Y return
- +66.87%
- -15.79%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2024
- News (4w)
- 4
- 7
- Recent ratings
- 25
- 8
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest MGX
- SEC Form 4 filed by Director Reid Laurence
- SEC Form 4 filed by Director Dere Willard H
- SEC Form 4 filed by Director Bjerkholt Eric
- SEC Form 4 filed by Director Eckhardt Juergen
- Chief Financial Officer Wapnick Pamela sold $3,746 worth of shares (2,884 units at $1.30), decreasing direct ownership by 1% to 208,491 units (SEC Form 4) to satisfy withholding tax
- Officer Irish Jian sold $4,854 worth of shares (3,737 units at $1.30), decreasing direct ownership by 0.98% to 377,533 units (SEC Form 4) (for tax liability)
- Officer Wein Matthew sold $725 worth of shares (558 units at $1.30), decreasing direct ownership by 0.44% to 126,491 units (SEC Form 4) to satisfy withholding tax
- Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
- SEC Form 10-Q filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits